TYW1B Antibody

What is TYW1B and what are its key biological functions?

TYW1B, also known as tRNA-yW synthesizing protein 1 homolog B, is involved in tRNA modification processes. Its full name is tRNA-yW synthesizing protein 1 homolog B (non-protein coding), with alternative designations including RSAFD2 (Radical S-adenosyl methionine and flavodoxin domain-containing protein 2) and S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B (EC 4.1.3.44) . The protein has a calculated molecular weight of 668 amino acids (77 kDa), which has been confirmed through experimental observations . TYW1B is encoded by a gene with ID 441250 (NCBI) and has been assigned the UniProt ID Q6NUM6 .

What sample types have been validated for TYW1B antibody applications?

TYW1B antibodies have been validated in multiple sample types:

Research indicates cross-reactivity with mouse and human samples is well-established, while rat reactivity has been reported but may require additional validation depending on your specific experimental needs .

What are the recommended storage conditions for TYW1B antibody?

For optimal antibody performance and longevity, TYW1B antibody should be stored at -20°C in its provided buffer (PBS with 0.02% sodium azide and 50% glycerol, pH 7.3) . The antibody remains stable for one year after shipment when properly stored . For smaller aliquots (20μl), the solution contains 0.1% BSA . It's important to note that aliquoting is generally unnecessary for -20°C storage of this particular antibody formulation, which differs from standard antibody storage recommendations . Avoid repeated freeze-thaw cycles to maintain antibody activity and specificity .

How do different antigen retrieval methods affect TYW1B detection in immunohistochemistry?

A comparative analysis of these methods reveals:

When optimizing your protocol, it's advisable to test both methods on your specific sample type, as tissue fixation methods and duration can significantly impact epitope accessibility. For human ovary and lung tissues, data indicates that TE buffer at pH 9.0 yields superior results with higher signal-to-noise ratios .

What are the molecular mechanisms explaining variation in TYW1B antibody binding efficacy across different experimental conditions?

The efficacy of TYW1B antibody binding is influenced by multiple molecular factors:

• Epitope accessibility: The TYW1B antibody targets specific epitopes within the TYW1B fusion protein (Ag11947) . Post-translational modifications, protein-protein interactions, or conformational changes may mask these epitopes in certain contexts.

• Cross-reactivity considerations: The antibody shows confirmed reactivity with human and mouse TYW1B , but potential cross-reactivity with related proteins containing similar radical S-adenosyl methionine domains should be considered when interpreting results.

• Buffer composition effects: The presence of detergents, salts, and protein blockers can significantly alter antibody-antigen interactions. For Western blot applications, optimization of transfer conditions and blocking reagents may be necessary for detecting the 77 kDa target protein .

• Fixation-dependent epitope changes: In immunohistochemistry applications, the fixative type, concentration, and duration dramatically affect epitope preservation. The recommended antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0) help reverse some fixation-induced conformational changes .

Understanding these mechanisms can help researchers systematically optimize experimental conditions rather than using trial-and-error approaches.

How can TYW1B antibody be validated in CRISPR/Cas9 knockout systems?

Validating TYW1B antibody specificity using CRISPR/Cas9 systems requires a careful experimental design:

• CRISPR/Cas9 targeting strategy: Design guide RNAs targeting conserved exons of the TYW1B gene. Based on CRISPR/Cas9 methodologies outlined in comparable studies, targeting multiple exons increases knockout efficiency .

• Validation workflow:

  • Generate TYW1B knockout cell lines (recommended in MCF-7 cells based on known antibody reactivity)

  • Confirm knockout at genomic level by sequencing

  • Verify protein loss using Western blot with the TYW1B antibody (1:500-1:1000 dilution)

  • Compare signal between wild-type and knockout cells

• Controls and considerations:

  • Include positive controls (mouse liver lysate or MCF-7 wild-type cells)

  • Prepare negative controls (knockout cells or isotype control antibody)

  • Consider siRNA knockdown as a complementary approach to confirm specificity

  • Use multiple antibody clones if available to verify results

This validation approach will provide definitive evidence of antibody specificity and can identify potential cross-reactive proteins, significantly strengthening the reliability of subsequent experimental findings.

What are the optimal dilution ranges for TYW1B antibody across different applications?

Optimal antibody dilutions vary substantially between applications:

It's important to note that these ranges represent starting points. The optimal dilution is highly dependent on sample type, detection method, and experimental conditions . For Western blot applications, protein loading amount and detection system sensitivity significantly impact the optimal antibody concentration. For immunohistochemistry, factors such as tissue type, fixation method, and antigen retrieval protocol will influence the required antibody concentration .

For all applications, it is strongly recommended to perform an antibody titration experiment to determine the optimal concentration for your specific experimental system .

What are the recommended protocols for Western blot detection of TYW1B?

For optimal Western blot detection of TYW1B, follow this validated protocol:

• Sample preparation:

  • Extract proteins from tissues (mouse liver recommended as positive control) or cells (MCF-7 recommended)

  • Use a lysis buffer containing protease inhibitors to prevent degradation

  • Determine protein concentration using Bradford or BCA assay

• SDS-PAGE:

  • Load 20-40 μg total protein per lane

  • Use 8-10% polyacrylamide gels for optimal resolution of the 77 kDa TYW1B protein

• Transfer and blocking:

  • Transfer proteins to PVDF or nitrocellulose membrane

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Antibody incubation:

  • Dilute primary TYW1B antibody 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3-5 times with TBST

  • Incubate with HRP-conjugated secondary anti-rabbit IgG (1:2000-1:5000)

  • Wash 3-5 times with TBST

• Detection:

  • Develop using ECL substrate

  • Expected molecular weight: 77 kDa

For troubleshooting weak signals, consider extending primary antibody incubation time, increasing antibody concentration, or using enhanced chemiluminescence substrates.

What protocol modifications are needed for immunohistochemical detection of TYW1B in different tissue types?

Immunohistochemical detection of TYW1B requires tissue-specific modifications:

• General IHC Protocol:

  • Deparaffinize and rehydrate formalin-fixed, paraffin-embedded sections

  • Perform antigen retrieval with TE buffer (pH 9.0) or citrate buffer (pH 6.0)

  • Block endogenous peroxidase activity with H₂O₂

  • Block non-specific binding with serum or BSA

  • Apply TYW1B antibody (1:20-1:200 dilution)

  • Incubate overnight at 4°C

  • Apply appropriate detection system

  • Counterstain, dehydrate, and mount

• Tissue-Specific Modifications:

• Critical Considerations:

  • Always include positive controls (human ovary or lung tissue)

  • Include negative controls (primary antibody omission and isotype controls)

  • For multiplex staining, test antibody compatibility in sequential staining protocols

These protocol modifications have been validated in experimental settings and will help ensure reliable and reproducible TYW1B detection across different tissue types.

How can non-specific binding issues with TYW1B antibody be identified and resolved?

Non-specific binding with TYW1B antibody can manifest in several ways:

• Identifying non-specific binding:

  • Multiple bands in Western blot beyond the expected 77 kDa

  • Diffuse or unexpected cellular staining patterns in IHC

  • Signal in negative control samples

  • Background staining that doesn't follow biological distribution patterns

• Resolution strategies:

• Additional considerations:

  • For tissues with high endogenous peroxidase activity, extend the peroxidase quenching step

  • For tissues with high biotin content, use non-biotin detection systems

  • Consider using monovalent Fab fragments to block endogenous immunoglobulins in tissue samples

Implementing these strategies systematically can significantly improve signal-to-noise ratio and ensure reliable detection of TYW1B.

How should discrepancies between Western blot and immunohistochemistry results for TYW1B be interpreted?

Discrepancies between Western blot and immunohistochemistry results for TYW1B require careful interpretation:

• Common discrepancy patterns:

  • Positive WB/Negative IHC: Often indicates issues with epitope accessibility in fixed tissues

  • Negative WB/Positive IHC: May suggest cross-reactivity in IHC or protein degradation in WB

  • Different cellular/subcellular localization: Could reflect genuine biological differences or technical artifacts

• Mechanistic explanations:

• Validation approaches:

  • Confirm results with orthogonal methods (immunofluorescence, flow cytometry)

  • Use cell/tissue types with known expression as controls (mouse liver, MCF-7 cells)

  • Consider RNA-level validation (qPCR, RNA-seq) to confirm expression patterns

Understanding these mechanisms allows researchers to determine whether discrepancies represent technical limitations or biologically meaningful phenomena, guiding appropriate experimental design modifications.

How does sample preparation affect TYW1B antibody detection sensitivity and specificity?

Sample preparation significantly impacts both sensitivity and specificity of TYW1B antibody detection:

• Protein extraction methods:

• Tissue fixation considerations:

• Critical variables affecting detection:

  • Protein phosphorylation status may affect epitope accessibility

  • Sample storage conditions (avoid repeated freeze-thaw)

  • Protease inhibitor cocktail composition (should include both serine and cysteine protease inhibitors)

  • Time elapsed between sample collection and processing (minimize to prevent degradation)

By controlling these variables, researchers can significantly improve both sensitivity and reproducibility in TYW1B detection across experimental systems.

How can TYW1B antibodies be incorporated into multi-parameter flow cytometry panels?

Incorporating TYW1B antibodies into multi-parameter flow cytometry requires careful panel design:

• Conjugation considerations:

  • The commercially available TYW1B antibodies are typically unconjugated , requiring secondary detection methods or custom conjugation

  • For direct detection, consider custom conjugation to fluorophores like AF488, PE, or APC using commercial conjugation kits

  • Validate conjugated antibodies against unconjugated versions to ensure epitope accessibility is maintained

• Panel design strategy:

• Protocol optimization:

  • Fixation: 2-4% paraformaldehyde for 10-15 minutes

  • Permeabilization: 0.1% saponin or commercial permeabilization buffers

  • Blocking: 2% FBS or BSA to reduce non-specific binding

  • Primary antibody (if using indirect staining): Incubate at optimal dilution for 30-60 minutes

  • Secondary antibody: Choose one with minimal cross-reactivity to other species in your panel

This approach allows incorporation of TYW1B detection into complex immunophenotyping panels for cellular subpopulation analysis.

What are the considerations for using TYW1B antibody in proximity ligation assays to study protein-protein interactions?

Proximity Ligation Assay (PLA) with TYW1B antibody requires specific considerations:

• Antibody compatibility requirements:

  • TYW1B antibody (rabbit polyclonal) must be paired with antibodies raised in different species (mouse, goat, etc.)

  • Both antibodies must recognize epitopes that are accessible in fixed samples

  • Validate antibody specificity individually before PLA

• Optimizing PLA protocol for TYW1B:

• Analyzing potential TYW1B interaction partners:
  Based on current knowledge of tRNA modification pathways, potential interaction partners to investigate include:

  • Other tRNA modification enzymes

  • S-adenosylmethionine-dependent methyltransferases

  • RNA processing machinery components

This approach enables direct visualization of TYW1B protein interactions in situ, providing spatial information about complex formation that complements biochemical interaction studies.

How can TYW1B antibody be used to investigate potential roles in disease mechanisms, such as anaplastic large cell lymphoma?

While direct evidence linking TYW1B to anaplastic large cell lymphoma (ALCL) is limited, the antibody can be used to investigate potential relationships:

• Expression analysis in ALCL samples:

  • Use TYW1B antibody (1:20-1:200 dilution) for IHC on ALCL tissue microarrays

  • Compare expression patterns between ALK+ and ALK- ALCL subtypes

  • Correlate with established markers like NOTCH1, which has been implicated in ALCL pathogenesis

• Mechanistic investigation approaches:

• Functional studies:

  • Combine TYW1B antibody-based detection with genetic approaches (siRNA, CRISPR) to establish causality

  • Investigate potential links between tRNA modification and NOTCH1 signaling

  • Study tRNA modification patterns in ALCL samples using complementary approaches

This systematic investigation could reveal previously unknown roles for TYW1B in lymphoma biology, potentially identifying new therapeutic targets or biomarkers of response to existing therapies like ALK inhibitors .